Each year, through the Linked Clinical Trials (LCT) initiative, drugs are selected by the Linked Clinical Trials committee, based on drug safety; the drug’s ability to pass the blood-brain barrier; mode of action relevant to putative disease mechanisms in Parkinson’s (PD); ability to measure the drug’s effectiveness; and whether there has been demonstrated success in several preclinical Parkinson’s models (Brundin et al 2013). 

Since the first annual LCT meeting in 2012, over 2000 drugs have been screened to be repurposed for Parkinson’s. These efforts have been instrumental in bringing directly to trial a number of important drugs with disease modifying potential.

Dossiers of each drug discussed are compiled by CPT’s Director and Deputy Director of Research & Development, Dr Richard Wyse and Dr Simon Stott. Included recently are drugs where promising new findings have been published including UDCA, Alogliptin and Nortriptyline - trials of these prospective new Parkinson's treatments begin recruiting in 2019.

There are currently more than 30 drugs in the trial pipeline at different stages of development. Some require further pre-clinical work, others need trial design or pharmaceutical partnership, for example : MSDC-0160, and NAC. Novel trial designs are also being developed such as multi-arm and multi-stage trials and innovative outcomes are also being implemented. 

**Stop Press**

Through the LCT, CPT has been evaluating PARP inhibitors since 2012. In 2018, once again these were highly prioritised by the committee and in November 2019, Dr Richard Wyse (the Director of Research at CPT) and Prof Patrick Brundin wrote an editorial for an exciting new research report suggesting that inhibition of a cancer-associated pathway (PARP1) has beneficial effects in models of Parkinson’s. Efforts are now being made to take PARP1 inhibitor drugs into the clinic for Parkinson’s. Read this paper here

Please help us drive forward our research to slow, stop, and reverse Parkinson's - donate today - thank you.